Altimmune (ALT) Income from Continuing Operations (2010 - 2026)
Altimmune (ALT) posted quarterly Income from Continuing Operations of 22563000.0 for Q1 2026, down 15.26% year-over-year from 26627523.06 in Q1 2025, and down 129.74% quarter-over-quarter from 75855000.0 in Q4 2025.
Altimmune (ALT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Income from Continuing Operations for 17 consecutive years, with 22563000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 15.26% year-over-year to 22563000.0; the TTM figure through Mar 2026 stood at 12132000.0 (up 113.44% YoY), while the FY2025 annual figure was 15120000.0, up 120.13% from the prior year.
- Income from Continuing Operations eased to 22563000.0 in Q1 2026 per ALT's latest filing, from 75855000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 75855000.0 in Q4 2025 and bottomed at 31641000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 15574882.35 across 5 years, with a median of 20671000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 228.09% — and 2025, when it jumped 427.24%.
- Altimmune's Income from Continuing Operations stood at 9644000.0 in 2022, then sank by 228.09% to 31641000.0 in 2023, then climbed by 26.74% to 23180000.0 in 2024, then surged by 427.24% to 75855000.0 in 2025, then tumbled by 129.74% to 22563000.0 in 2026.
- Business Quant data shows ALT's Income from Continuing Operations at 22563000.0 in Q1 2026, 75855000.0 in Q4 2025, and 19014000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | -22.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.83 Mn |
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 75.86 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -31.64 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -20.19 Mn |
| Dec 31, 2022 | -9.64 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.58 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |